TAO Synergies TAOX
NASDAQ TAOX
$4.14 +0.13 (+3.24%)
As of: Sep 9, 2026 · 11:58 AM EDT

TAO Synergies (TAOX) Income towards Parent Company (2019 - 2026)

TAO Synergies' (TAOX) quarterly Income towards Parent Company came in at -$9.3 million in Q2 2026, up 46.91% on a YoY basis from -$6.3 million in Q2 2025, and down 318.57% quarter-over-quarter from $4.3 million in Q1 2026.

Analysis

TAO Synergies (TAOX) Income towards Parent Company (2019 - 2026) Analysis & Trends

TAO Synergies (TAOX) has reported Income towards Parent Company for 8 consecutive years, with -$9.3 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Income towards Parent Company rose 46.91% year-over-year to -$9.3 million; the trailing twelve-month figure through Jun 2026 stood at -$16.7 million (up 41.41% YoY), and the FY2025 full-year result was -$22.7 million, down 125.06% from the prior year.
  • Income towards Parent Company eased to -$9.3 million in Q2 2026 per TAOX's latest filing, from $4.3 million in the prior quarter.
  • Across five years, Income towards Parent Company topped out at $4.5 million in Q4 2022 and bottomed at -$17.5 million in Q2 2025.
  • Historically, Income towards Parent Company has averaged -$3.2 million across 5 years, with a median of -$3.2 million in 2022.
  • The sharpest annual moves came in 2025 and 2026: Income towards Parent Company plunged 1275.63% in 2025, then soared 1004.55% in 2026.
  • Over 5 years, Income towards Parent Company stood at $4.5 million in 2022, then tumbled by 122.22% to -$995969.0 in 2023, then sank by 456.9% to -$5.5 million in 2024, then sank by 38.52% to -$7.7 million in 2025, then declined by 21.03% to -$9.3 million in 2026.
  • According to Business Quant data, Income towards Parent Company over the past three periods registered -$9.3 million, $4.3 million, and -$7.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 211.88 Bn 197.89 Bn 7.24 Bn
2 Gilead Sciences 181.55 Bn 178.37 Bn 6.22 Bn
3 Vertex Pharmaceuticals 132.31 Bn 124.45 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 82.51 Bn 74.52 Bn 3.93 Bn
5 Argenx Se 61.54 Bn 56.36 Bn 1.37 Bn
6 Moderna 54.69 Bn 49.55 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 34.07 Bn 30.76 Bn 992.69 Mn
8 Biogen 31.41 Bn 30.12 Bn 1.96 Bn
9 Roivant Sciences 30.10 Bn 30.10 Bn 1.16 Mn
10 TAO Synergies 30.93 Mn 30.93 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -9.30 Mn
Mar 31, 2026 4.25 Mn
Dec 31, 2025 -7.68 Mn
Sep 30, 2025 -3.92 Mn
Jun 30, 2025 -17.52 Mn
Mar 31, 2025 385,169.00
Dec 31, 2024 -5.55 Mn
Sep 30, 2024 -5.74 Mn
Jun 30, 2024 -1.27 Mn
Mar 31, 2024 -206,699.00
Dec 31, 2023 -995,969.00
Sep 30, 2023 763,203.00
Jun 30, 2023 -4.09 Mn
Mar 31, 2023 -1.71 Mn
Dec 31, 2022 4.48 Mn
Sep 30, 2022 -3.03 Mn
Jun 30, 2022 -3.75 Mn
Mar 31, 2022 -3.28 Mn
Dec 31, 2021 -4.24 Mn
Sep 30, 2021 -2.93 Mn